16 / 156
432
20. Cahill AG and Caughey AB. Magnesium for neuroprophylaxis:
fact or fiction?. Am J Obstet Gynecol 2009; 200 (6): 590-594.
21. Jacquemyn Y., Zecic A., Van Laere D. and Roelens K. The use
of intravenous magnesium in non-preeclamptic pregnant
women: fetal/neonatal neuroprotection. Arch Gynecol Obtet
2015;291:969-975.
22. Abbassi-Ghanavati M, Alexander JM, McIntire DD, Savani RC,
Leveno KJ. Neonatal effects of magnesium sulfate given to the
mother. Am J Perinatol 2012; 29:795–799.
23. Food and Drug Administration (2013) FDA recommends
against prolonged use of magnesium to stop pre-term labor
due to bone changes in exposed babies. FDA Drug Safety
Communication. Silver Spring (MD).
http://www.fda.gov/downloads/Drugs/Drug Safety/UCM353335.pdf.
24. Mittendorf R, Damman O, Lee KS. Brain lesions in newborns
exposed to high-dose magnesium sulfate during preterm
labor. J Perinatol 2006;26:57–63.
25. Mittendorf R, Pryde P, Khoshnood B, Lee KS. If tocolytic
magnesium sulfate is associated with excess total pediatric
mortality, what is its impact? Obstet Gynecol 1998;92:308–
311.
26. Shokry M., Elsedfy G., Bassiouny M., Anmin M., Abozid H.
Effects of antenatal magnesium sulfate therapy on cerebral
and systemic hemodynamics in preterm newborns. Acta
Obstetricia et Gynecologica. 2010; 89: 801–806.
27. Katayama Y., Minami H., Enomoto M., Takano T., Hayashi S.
and Lee YK. Antenatal magnesium sulfate and the postnatal
response of the ductus arteriosus to indomethacin in
extremely preterm neonates. Journal of Perinatology 2011;
31: 21–24.
28. Ben Ami M, Giladi Y, Shalev E. The combination of magnesium
sulfate and Nifedipine: a cause of neuromuscular blockade. Br
J Obstet Gynecol 1994;101:262–263.
29. Magee LA, Miremadi S, Li J.Therapy with both magnesium
sulfate and Nifedipine does not increase the risk of serious
magnesium-related maternal side effects in women with
preeclampsia. Am J Obstet Gynecol 2005;193:153–163.
30. Snyder SW, Cardwell MS. Neuromuscular blockade with
magnesium-sulfate and Nifedipine. Am J Obstet Gynecol
1989;161:35–36.
31. Shimosawa T, Takano K, Ando K, Fujita T. Magnesium inhibits
norepinephrine release by blocking N-type calcium channels
at peripheral nerve endings. Hypertenssion 2004;44:897–
902.
32. Nowak L., Bregestovski P., Ascher P., Herbet A., and Prochiantz
A. Magnesiumgates glutamate-activated channels in mouse
central neurons. Nature 1984;307(5950):462–465.
33. Hallak M., Hotra JW., and Kupsky WJ. Magnesium sulfate
protection of fetal rat brain from severe maternal hypoxia.
Obstet Gynecol 2000; 96(1): 124–128.
34. Cross JL, Meloni BP, Bakker AJ, Lee S, Knuckey NW. Modes of
neuronal calcium entry and homeostasis following cerebral
ischemia. Stroke Res Treat. 2000. doi:10.4061/2010/316862
35. Euser AG. and Cipolla MJ. Magnesium sulfate for the
treatment of eclampsia: a brief review. Stroke 2009; 40 (4):
1169–1175.
36. Farago M., Szabo C., Dora E., Horvath I, and Kovach A.
Contractile and endothelium-dependent dilatory responses
of cerebral arteries at various extracellular magnesium
concentrations. Journal of Cerebral Blood Flow and
Metabolism 1991;11(1):161–164.
37. Galinsky R, Davidson J., Drury P. et al. Magnesium sulphate
and cardiovascular and cerebrovascular adaptations to
asphyxia in preterm fetal sheep. J Physiol 2016; 594.5:1281–
1293 e Journal of Physiology.
38. Garnier Y., Middelanis J., Jensen A., and Berger R.
Neuroprotective effects of magnesium on metabolic
disturbances in fetal hippocampal slices after oxygen-glucose
deprivation: mediation by nitric oxide system. Journal of the
Society for Gynecologic Investigation 2002; 9(2): 86–92.
39. Cahill A, Stout M, Caughey A. Intrapartum magnesium for
prevention of cerebral palsy: continuing controversy ? Obstet
Gynecol 2010; 22:122–127.
40. Rhee E, Beiswenger T, Oguejiofor CE, James AH. The effects
of magnesium sulfate on maternal and fetal platelet
aggregation. J Matern Fetal Neonatal Med 2012;25(5):478–
483.
41. The Antenatal Magnesium Sulfate for Neuroprotection
Guideline Development panel (2010) Antenatal magnesium
sulfate prior to preterm birth for neuroprotection of the fetus,
infant and child: National clinical practice guideline. The
University of Adelaide, Adelaide.
42. Magee L, Sawchuck D, Synnes A, Von Dadelszen P. SOGC
Clinical Practice Guideline. Magnesium sulphatefor fetal
neuroprotection. J Obstet Gynaecol Can 2011;33(5):516–
529.
43. ACOG Committee on Obstetric Practice Society for Maternal-
Fetal Medicine. Committee opinion No 455: Magnesium
before anticipated preterm birth for neuroprotection. Obstet
Gynecol 2010; 115:669–671.
44. ACOG Committee Opinion No 573 Magnesium Sulfate Use in
Obstetrics. Obstet Gynecol 2013;122:727–728.
45. Yao AC. and Lind J. Blood flow in theumbilical vessels during
the third stage of labor. Biology of the Neonate 1974;25(3-
4):186–193.
46. Hofmeyr GJ., Bolton KD., Bowen DC., and Govan JJ.
Periventricular/intraventricular haemorrhage and umbilical
cord clampings. Findings and hypothesis. South African
Medical Journal 1988; 73(2):104–106.
47. Baenziger O., Stolkin F., Keel M et al. The influence of the
timing of cord clamping on postnatal cerebral oxygenation in
preterm neonates: a randomized, controlled trial, Pediatrics
2007;119(3):455–459.
48. Bonnar J., McNicol GP, and Douglas AS. The blood coagulation
and fibrinolytic systems the newborn and the mother at
birth. Journal of Obstetrics and Gynaecology of the British
Commonwealth 1971;78(4):355–360.
49.-Park DH., Borlongan CV., Willing AE et al. Human umbilical
[REV. MED. CLIN. CONDES - 2016; 27(4) 427-433]